Theralase Technologies Inc. (TSXV:TLT)

Market Cap	46.03M
Revenue (ttm)	1.03M
Net Income (ttm)	-4.26M
Shares Out	248.81M
EPS (ttm)	-0.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	351,788
Average Volume	111,512
Open	0.1950
Previous Close	0.1900
Day's Range	0.1850 - 0.2050
52-Week Range	0.1400 - 0.3800
Beta	1.14
RSI	46.68
Earnings Date	May 30, 2025

About Theralase Technologies

Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research, development, and commercialization of light activated photo dynamic compounds and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. The company operates through Drug Division and Device Division segments. It designs, develops, manufactures, and markets super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle...

• Industry: Medical Devices
• Sector: Healthcare
• CEO: Roger Dumoulin-White
• Employees: 20
• Stock Exchange: TSX Venture Exchange
• Ticker Symbol: TLT

Financial Performance

In 2024, Theralase Technologies's revenue was 1.03 million, a decrease of -3.45% compared to the previous year's 1.07 million. Losses were -4.26 million, -6.89% less than in 2023.